COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH plus CML-CP) IN ITALY

被引：0
|
作者：
Maheshwari, V [1 ]
Tran, D. [2 ]
Agostoni, G. [3 ]
Filioussi, K. [3 ]
Viana, R. [4 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[2] Cornerstone Res Grp Inc, Burlington, ON, Canada
[3] Novartis Farma SpA, Origgio, Italy
[4] Novartis, East Hannover, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN176
引用
收藏
页码：S470 / S470
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting
    B. Muresan
    C. Mamolo
    J. C. Cappelleri
    M. J. Postma
    B. Heeg
    Applied Health Economics and Health Policy, 2021, 19 : 929 - 940
  • [42] A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea
    Shin, Junghoon
    Koh, Youngil
    Yoon, Seo Hyun
    Cho, Joo-Youn
    Kim, Dae-Young
    Lee, Kyoo-Hyung
    Kim, Hyeong-Joon
    Ahn, Jae-Sook
    Kim, Yeo-Kyeoung
    Park, Jinny
    Sohn, Sang-Kyun
    Moon, Joon Ho
    Lee, Yoo Jin
    Yoon, Seonghae
    Lee, Jeong-Ok
    Cheong, June-Won
    Ha Kim, Kyoung
    Kim, Sung-Hyun
    Kim, Hoon-Gu
    Kim, Hawk
    Nam, Seung-Hyun
    Do, Young Rok
    Park, Sang-Gon
    Park, Seong Kyu
    Bae, Sung Hwa
    Song, Hun Ho
    Shin, Dong-Yeop
    Oh, Doyeun
    Kim, Min Kyoung
    Jung, Chul Won
    Park, Seonyang
    Kim, Inho
    CANCER MEDICINE, 2018, 7 (05): : 1814 - 1823
  • [43] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
    Scalzulli, Emilia
    Caocci, Giovanni
    Efficace, Fabio
    Rizzo, Lorenzo
    Colafigli, Gioia
    Di Prima, Alessio
    Pepe, Sara
    Fegatelli, Danilo Alunni
    Carmosino, Ida
    Diverio, Daniela
    Latagliata, Roberto
    La Nasa, Giorgio
    Martelli, Maurizio
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1213 - 1219
  • [44] Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients
    Emilia Scalzulli
    Giovanni Caocci
    Fabio Efficace
    Lorenzo Rizzo
    Gioia Colafigli
    Alessio Di Prima
    Sara Pepe
    Danilo Alunni Fegatelli
    Ida Carmosino
    Daniela Diverio
    Roberto Latagliata
    Giorgio La Nasa
    Maurizio Martelli
    Robin Foà
    Massimo Breccia
    Annals of Hematology, 2021, 100 : 1213 - 1219
  • [45] Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
    Saydam, Guray
    Haznedaroglu, Ibrahim Celalettin
    Kaynar, Leylagul
    Yavuz, Akif S.
    Ali, Ridvan
    Guvenc, Birol
    Akay, Olga M.
    Baslar, Zafer
    Ozbek, Ugur
    Sonmez, Mehmet
    Aydin, Demet
    Pehlivan, Mustafa
    Undar, Bulent
    Dagdas, Simten
    Ayyildiz, Orhan
    Akkaynak, Diyar Z.
    Dag, Ilkiz M.
    Ilhan, Osman
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (14) : 1851 - 1858
  • [46] Severe thrombocytopenia after dasatinib treatment in a patient with Philadelphia chromosome-positive chronic myeloid leukemia
    Chen, Runzhe
    Wang, Fei
    Zhang, Xiaoping
    Gao, Chong
    Chen, Baoan
    OncoTargets and Therapy, 2015, 8 : 955 - 957
  • [47] Dasatinib population pharmacokinetics in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ph plus all)
    Dai, Guowei
    Roy, Amit
    Mandava, Mohan
    Blackwood-Chirchir, Anne
    Luo, Roger
    Wu, Chiyuan
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (09): : 1085 - 1085
  • [48] Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia
    Hoyle, Martin
    Rogers, Gabriel
    Moxham, Tiffany
    Liu, Zulian
    Stein, Ken
    VALUE IN HEALTH, 2011, 14 (08) : 1057 - 1067
  • [49] Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)
    Cortes, Jorge E.
    Lipton, Jeffrey H.
    Miller, Carole B.
    Ailawadhi, Sikander
    Akard, Luke
    Pinilla-Ibarz, Javier
    Lin, Felice P.
    Ericson, Solveig G.
    Mauro, Michael J.
    BLOOD, 2012, 120 (21)
  • [50] ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib
    Mahon, Francois-Xavier
    Boquimpani, Carla
    Takahashi, Naoto
    Benyamini, Noam
    Clementino, Nelma Cristina D.
    Shuvaev, Vasily
    Lipton, Jeffrey H.
    Turkina, Anna G.
    De Paz Arias, Raquel
    Moiraghi, Beatriz
    Nicolini, Franck E.
    Dengler, Jolanta
    Sacha, Tomasz
    Kim, Dong-Wook
    Fellague-Chebra, Rafik
    Tiwari, Ranjan
    Bouard, Catherine
    Hughes, Timothy P.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S288 - S289
12345